Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine

Microbes and Infection

Volumn 9, Issue 6, 2007, Pages 761-766

  Ripley Ballou, W ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Attenuated; Malaria; Sporozoite; Subunit; Vaccine

Indexed keywords

ADJUVANT; AS 02A; MALARIA VACCINE; RECOMBINANT PROTEIN; RTSS PROTEIN; SPOROZOITE VACCINE; UNCLASSIFIED DRUG;

CONTAMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; ERYTHROCYTE; FEASIBILITY STUDY; HUMAN; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; VACCINATION;

ANIMALS; DRUG DESIGN; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM; PROTOZOAN PROTEINS; SPOROZOITES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 34247545662     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2007.02.006     Document Type: Short Survey

References (30)

1. Ballou W.R., Arevelo-Herrera M., Carucci D., Richie T.L., Corradin G., Diggs C., Druihle P., Giersing B.K., Saul A., Heppner D.G., Kester K.E., Lanar D.E., Lyon J., Hill A.V.S., Pan W., and Cohen J.D. Update on the clinical development of candidate malaria vaccines. Am. J. Trop. Med. Hyg. 71 (2004) 239-247
2. Moore A.C., and Hill A.V.S. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199 (2004) 126-143
3. Nussenzweig R.S., Vanderberg J., Most H., and Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 216 (1967) 160-162
4. Nussenzweig V., and Nussenzweig R.S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45 (1989) 283-334
5. Nardin E.H., Nussenzweig R.S., Altszuler R., Herrington D., Levine M., Murphy J., Davis J., Bathurst I., Barr P., and Romero P. Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers. Bull. WHO 68 (1990) 85-87
6. Egan J.E., Hoffman S.L., Haynes J.D., Sadoff J.C., Schneider I., Grau G.E., Hollingdale M.R., Ballou W.R., and Gordon D.M. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 49 (1993) 166-173
7. Krzych U., Lyon J.A., Jareed T., Schneider I., Hollingdale M.R., Gordon D.M., and Ballou W.R. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. J. Immunol. 155 (1995) 4072-4077
8. Scheller L.F., and Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Nat. Acad. Sci. U.S.A. 92 (1995) 4066-4068
9. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., Sacci J., de la Vega P., Dowler M., Paul C., Gordon D.M., Stoute J.A., Church L.W., Sedegah M., Heppner D.G., Ballou W.R., and Richie T.L. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185 (2002) 1155-1164
10. Berenzon D., Schwenk R.J., Letellier L., Guebre-Xabier M., Williams J., and Krzych U. Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells. J. Immunol. 171 (2003) 2024-2034
11. Luke T.C., and Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206 (2003) 3803-3808
12. Menard F. Knockout malaria vaccine?. Nature 433 (2005) 113-114
13. Belnoue E., Costa F.T.M., Frankenberg T., Vigario A.M., Voza T., Leroy N., Rodrigues M.M., Landau I., Snounou G., and Renia L. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol. 172 (2004) 2487-2495
14. Schellenberg D., Menendez C., Kahigwa E., Font F., Galindo C., Acosta C., Schellenberg J.A., Aponte J.J., Kimario J., Urassa H., Mshinda H., Tanner M., and Alonso P. African children with malaria in an area of intense Plasmodium falciparum transmission: features on admission to the hospital and risk factors for death. Am. J. Trop. Med. Hyg. 61 (1999) 431-438
15. Gupta S., Snow R.W., Donnelly C.A., Marsh K., and Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat. Med. 5 (1999) 340-343
16. Lyke K.E., Dicko A., Kone A., Coulibaly D., Guindo A., Cissoko Y., Traore K., Plowe C.V., and Doumbo O.K. Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine 22 (2004) 3169-3174
17. Lengeler C. Insecticide-treated bednets and curtains for preventing malaria. Cochrane Database Syst. Rev. 2 (2000) CD000363
18. Schellenberg D., Menendez C., Kahigwa E., Aponte J.J., Vidal J., Tanner M., Mshinda H., and Alonso P. Intermittent treatment for malaria and anaemia control at time of routine vaccination in Tanzanian infants; a randomised, placebo-controlled trial. Lancet 357 (2001) 1471-1477
19. Massaga J.J., Kitua A.Y., Lemnge M., Akida J.A., Malle L.N., Rønn A.M., Theander T.G., and Bygbjerg I.C. IC. Effect of intermittent treatment with amodiaquine on anaemia and malaria fevers in Tanzania; a randomised, placebo-controlled trial. Lancet 361 (2003) 1853-1860
20. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., Mandomando I., Spiessens B., Guinovart C., Espasa M., Bassat Q., Aide P., Ofori-Anyinam O., Navia M.M., Corachan S., Ceuppens M., Dubois M.C., Demoitie M.A., Dubovsky F., Menendez C., Tornieporth N., Ballou W.R., and Thompson R. J. Cohen. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 (2004) 1411-1420
21. Hurd H., Al-Olayan E., and Butcher G.A. GA. In vitro methods for culturing vertebrate and mosquito stages of Plasmodium. Microbes Infect. 5 (2003) 321-327
22. Al-Olayan E.M., Beetsma A.L., Butcher G.A., Sinden R.E., and Hurd H. Complete development of mosquito phases of the malaria parasite in vitro. Science 295 (2002) 677-679
23. Farrugia A. Plasma for fractionation: safety and quality issues. Haemophilia 10 (2004) 334-340
24. Heppner D.G., Cummings J.F., Ockenhouse C.F., Kester K.E., Cohen J.D., and Ballou W.R. In: Levine M.M., Kaper J.B., Rappuoli R., Liu M.A., and Good M.F. (Eds). New Generation Vaccines. third ed. (2004), Dekker, New York 851-860
25. Sun P., Schwenk R., White K., Stoute J.A., Cohen J., Ballou W.R., Voss G., Kester K.E., Heppner D.G., and Krzych U. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4(+) and CD8(+) T cells producing IFN-gamma. J. Immunol. 171 (2003) 6961-6967
26. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., Krzych U., Delchambre M., Voss G., Dowler M.G., Palensky J., Wittes J.T., Cohen J., and Ballou W.R. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183 (2001) 640-647
27. Bejon P., Andrews L., Andersen R.F., Dunachie S., Webster D., Walther M., Gilbert S.C., Peto T., and Hill A.V. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191 (2005) 619-626
28. Alonso P.L., Sacarlal J., Sacarlal J.J., Leach A., Macete E., Aide P., Sigauque B., Milman J., Mandomando I., Bassat Q., Guinovart C., Espasa M., Corachan S., Lievens M., Navia M., Dubois M.C., Menendez C., Dubovsky F., Cohen J., Thompson R., and Ballou W.R. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
29. Vuola J.M., Keating S., Webster D.P., Berthoud T., Dunachie S., Gilbert S.C., and Hill A.V. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174 (2005) 449-455
30. Mueller A.K., Labaied M., Kappe S.H., and Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433 (2005) 164-167